Hold the phone large subgroup it is.
"We are very pleased. If this recommendation becomes final, ILUVIEN will be available in the U.K. to pseudophakic as well as private pay and privately insured patients," said Dr. Paul Ashton, Chief Executive Officer of pSivida. "The pseudophakic DME population represents a large subgroup as patients with DME have a far higher incidence of cataract than the overall population. In the Phase III FAME™ trials of ILUVIEN, over 50% of control patients were pseudophakic at the end of the trial."
http://investors.psivida.com/releasedetail.cfm?ReleaseID=771449
- Forums
- ASX - By Stock
- the loyal band
Hold the phone large subgroup it is."We are very pleased. If...
-
-
- There are more pages in this discussion • 4 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PVA (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
SER
STRATEGIC ENERGY RESOURCES LIMITED
David DeTata, Managing Director
David DeTata
Managing Director
SPONSORED BY The Market Online